Trial Profile
A Randomized, Controlled,Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning Compared With Fast Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-VI Attention-Deficit/Hyperactivity Disorder (ADHD).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms ADHD SWITCH
- Sponsors Eli Lilly and Company
- 23 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 23 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.